Sight Sciences

Our Ocular Surface Disease (OSD) team conducted an in-depth analysis of the SAHARA RCT data with the MUSC Storm Eye team. The twelve-month results of the SAHARA RCT were recently published, demonstrating improved signs and symptoms of Dry Eye Disease for TearCare patients crossed over from Restasis. The results show that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when our TearCare technology is used as a primary or secondary treatment for dry eye disease. More about the Sahara RCT here: https://lnkd.in/gHRPGaFm . . . . . . . . . . The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events. #sightsciences #treacare #dryeye #saharastudy #sahararct

Our VP of Marketing, H. B. Pierre Simon Jr., recently shared insights with Xtalks on the latest advancements in eye care technology. Pierre discussed how Sight Sciences is at the forefront of eye care revolution, building a strong portfolio to address both current and future needs in #glaucoma and #dryeye intervention Read the full interview here: https://lnkd.in/ggZuyNzs

The DOC Congress in Nuremberg, Germany, has been a fantastic experience! We have had great discussions about the power of our OMNI® Surgical System and the benefits of interventional glaucoma and implant-free MIGS. Today is the final day of the exhibition, and we look forward to connecting with you!

Our team in Germany looks forward to meeting you at the DOC Congress! Visit our booth to explore the benefits of interventional glaucoma and implant-free MIGS, and discover the latest clinical studies on our OMNI® Surgical System.

We extend our gratitude to all the glaucoma specialists who dedicated their weekend to attending the #SightSciences OMNI Masterclass in Birmingham, UK. The event featured lectures, dry-lab training, and many engaging discussions. Special thanks to our esteemed speakers, Professor Imran Masood and Ms. Lina Osman, for sharing their extensive experience performing implant-free MIGS with OMNI. . . . . . . . . . . The OMNI® Surgical System enables a comprehensive, implant-free, minimally invasive glaucoma surgery (#MIGS) that targets three areas of resistance: the trabecular meshwork, Schlemm’s canal, and the collector channels. OMNI is an implant-free glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle #glaucoma, and CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Visit www.omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events. #ophthalmology #ophthalmologist #omnisurgical #omnimasterclass

We had an outstanding time at the European Glaucoma Society meeting in Dublin! Demonstrating our OMNI technology and discussing our approach to interventional glaucoma treatment with such a dedicated group of professionals was truly inspiring. A big thank you to everyone who visited our booth and connected with our team. We are excited to continue these conversations at DOC in Nuremberg and ESCRS in Barcelona later this year! #egs2024 #glaucoma #ophthalmology #omnisurgical

A fantastic start to the 2024 European #Glaucoma Society Congress in Dublin! Many engaging discussions about implant-free, minimally invasive glaucoma surgery with OMNI! #EGS2024

We are excited to announce the publication of twelve-month (phase 2) results from the SAHARA RCT. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. The RCT demonstrates the clinical effectiveness of TearCare and shows that its effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED. The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis. As the SAHARA RCT continues into Phase 3, it will provide long-term 2-year data for the durability and procedural treatment effect of TearCare. Discover more details in this press release: https://lnkd.in/gHRPGaFm . . . . . . . . . . The #TearCare System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. The #TearCareSystem may not be right for everyone. Please see Instructions for Use or visit www.TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.

Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma. We are excited to announce the publication of a new analysis from the ROMEO study showing meaningful pressure and medication reductions achieved with OMNI® across mild, moderate, and advanced glaucoma! The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery. Discover more details in this press release: https://lnkd.in/gphBNef5 . . . . . . . . . . The OMNI® Surgical System is an implant-free glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle #glaucoma, and CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Visit www.omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events.

Two exciting meetings in Dublin, Ireland this week! Join Sight Sciences at the Interventional Glaucoma Consortium (IGC) meeting and the European Glaucoma Society (EGS) Congress. Discover the benefits of intervening earlier in disease progression and learn how OMNI offers a unique, implant-free, ab interno procedure intended to restore aqueous outflow in glaucomatous eyes by addressing the three areas of outflow resistance associated with the #glaucoma disease. We look forward to seeing you there! . . . . . . . . . . The OMNI® Surgical System is an implant-free glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Visit omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events. #ophthalmology #egs2024 #igc2024 #igcglobal #omnisurgical